KalVista Pharmaceuticals (KALV) closed FY 2025 with fourth quarter revenue of US$59.9 million and a basic EPS loss of US$0.10, alongside net income excluding extra items of a US$5.4 million loss. This provides a clear snapshot of a business still in investment mode. The company has seen quarterly revenue shift from US$13.7 million in FY 2025 Q3 to US$59.9 million in FY 2025 Q4, while basic EPS moved from a US$0.92 loss to a US$0.10 loss over the same period, highlighting a set of results where higher sales are occurring alongside sizeable ongoing losses. For investors, the focus is on how quickly those revenues can support healthier margins and narrow the gap between growth potential and current loss-making operations.

See our full analysis for KalVista Pharmaceuticals.

With the headline numbers set, the next step is to line them up against the most widely held narratives around KalVista Pharmaceuticals to see which views the latest results support and which they call into question.

Losses remain heavy at US$164.3 million over 12 months

• Over the trailing 12 months to FY 2025 Q4, KalVista reported a net loss excluding extra items of US$164.3 million on total revenue of US$73.6 million, with basic EPS at a loss of US$3.05.
• Bulls focus on the idea that this loss profile is temporary, yet it sits against very large growth assumptions:
  • Optimistic forecasts in the bullish narrative look for earnings to move from a loss of about US$203.1 million to a profit of US$7.5 million, which is a large swing relative to the current loss base.
  • Bulls also anchor on a DCF fair value of US$86.75 compared with the current share price of US$18.95. In that context, the present loss of US$164.3 million is being viewed as the price of getting to that future scenario.

Bulls argue that these losses are the entry ticket to long term growth in hereditary angioedema, but you can see how much needs to change for earnings to catch up with the story in the 🐂 KalVista Pharmaceuticals Bull Case

Revenue still small against years of rising losses

• The risk summary flags about US$1 million of revenue over the last 12 months in one dataset alongside losses that have grown at about 31.4% per year over five years, underscoring that current commercial scale is limited compared with the size and duration of the losses.
• Skeptics lean on this mismatch between revenue and losses, and the numbers here give that view some support:
  • The bearish narrative highlights that the company is carrying quarterly SG&A of US$46.5 million, while one of the quarterly EKTERLY sales figures provided is US$13.7 million. This illustrates that operating costs currently sit well above at least one reported revenue point.
  • Bears also point out that recent financing is being used to fund operations through this phase, so the combination of minimal trailing revenue and sizeable ongoing SG&A keeps the focus on execution risk rather than current earnings power.

Skeptics warn that until revenue meaningfully catches up with spending, the cautious view will keep pointing back to this wide gap between commercial scale and the cost base in the 🐻 KalVista Pharmaceuticals Bear Case

Rich 21.2x P/B alongside mixed valuation signals

• Relative valuation data shows KalVista trading on a P/B of 21.2x versus 2.4x for the US biotech industry and 4.8x for peers, while a DCF fair value of US$86.75 and an analyst price target of US$34.33 both sit above the current share price of US$18.95.
• The consensus style narrative has to reconcile these conflicting markers, and the figures point to a split picture:
  • On one side, the high P/B multiple compared with industry and peers means the market is already assigning a premium to the balance sheet even though the trailing 12 month net loss is US$164.3 million.
  • On the other side, a DCF fair value that is well above US$18.95 and an analyst target of US$34.33 both imply that some observers view current pricing as low compared with their cash flow and earnings assumptions, despite revenue of only US$73.6 million over the last year.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for KalVista Pharmaceuticals on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Mixed signals or a clear story taking shape; either way, this is a moment to review the numbers for yourself and move quickly to your own view, starting with the 2 key rewards and 1 important warning sign.

Explore Alternatives

KalVista Pharmaceuticals pairs relatively small trailing revenue of US$73.6 million with a US$164.3 million loss and a rich 21.2x P/B multiple. This combination highlights both execution risk and valuation risk.

If you want ideas where pricing expectations appear tighter relative to financial strength and earnings potential, start shortlisting opportunities using the 69 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.